Updates from HER2CLIMB in HER2+ Metastatic Breast Cancer

Opinion
Video

An expert on metastatic breast cancer provides clinical insights gleaned from the HER2CLIMB-02 trial and discusses the design and rationale of the ongoing HER2CLIMB-05 study.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Related Content